Plexense has focused on advancing and simplifying cost-effective immunoassay technology since its foundation in 2012. The new and innovative ACCEL ELISA® is a rapid and precise immunoassay platform developed by Plexense with the capability of delivering 94 ELISA tests in less than 30 minutes. With only two-reaction steps, the results of the ACCEL ELISA® outperform conventional ELISA formats not just in speed and simplicity, but also in terms of accuracy by multiple folds in the detection limit.
ACCEL ELISA® products include the COVID-19 antibody test kit, COVID-19 neutralizing antibody test kit, and the COVID-19 saliva antigen test kit, in addition to its saliva cortisol test kit, veterinarian disease test kits, mycotoxin test kits, and cancer marker test kits.
We continue to extend the applications of ACCEL ELISA® in diverse fields of testing areas including clinical diagnostics, environmental testing, veterinarian diagnostics, and food-safety. In an effort to help improve the overall well-being of communities and places where better life is needed, we strive to provide low-cost healthcare tools that go beyond limits and boundaries regardless of location or status.
Plexense, Inc. is located in Seoul and Yongin, Korea, and its subsidiary, Plexense BIO, Inc., is located in Sacramento, California, USA.